Gambi F, De Berardis D, Sepede G, Campanella D, Galliani N, Carano A, La Rovere L, Salini G, Penna L, Cicconetti A, Spinella S, Quartesan R, Salerno R M, Ferro F M
Department of Oncology and Neurosciences, Institute of Psychiatry, University G. d' Annunzio, Chieti, Italy.
Int J Immunopathol Pharmacol. 2005 Oct-Dec;18(4):737-44. doi: 10.1177/039463200501800417.
Hypothalamic pituitary thyroid (HPT) axis abnormalities and alterations in major depression are reported in the literature. The aim of our study was to evaluate the effect of mirtazapine on thyroid hormones after 6 months of therapy in a sample of adult outpatients with Major Depression (MD). 17 adult outpatients (7 men, 10 women) with MD according to DSM-IV criteria, were included in the study. All participants had to have met criteria for a major depressive episode with a score of at least 15 on the Hamilton Depression Rating Scale (HAM-D). Fasting venous blood samples were obtained for determination of serum Thyroid Stimulating Hormone (TSH), Free T3 (FT3) and Free T4 (FT4) concentrations both at baseline and after 6 months of therapy. HAM-D scores decreased significantly from the first day of treatment to the end of the treatment period (P<0.001) and twelve patients (70.6%) were classified as responders. A significant increase in FT3 concentrations was found between baseline and the end of the treatment period (P=0.015), whereas FT4 concentrations decreased (P=0.046). No significant changes were found in TSH levels. Higher FT4 concentrations at baseline predicted higher HAM-D scorers both at baseline and at the end of the treatment period. Furthermore, higher FT3 concentrations at endpoint were found to be predictors of lower HAM-D scores. Long-term treatment with mirtazapine increases FT3 levels and decreases FT4 maybe involving the deiodination process of T4 into T3.
文献报道了下丘脑-垂体-甲状腺(HPT)轴异常与重度抑郁症的改变。我们研究的目的是评估米氮平对成年门诊重度抑郁症(MD)患者治疗6个月后甲状腺激素的影响。根据DSM-IV标准,17名成年门诊MD患者(7名男性,10名女性)纳入研究。所有参与者必须符合重度抑郁发作的标准,汉密尔顿抑郁量表(HAM-D)评分至少为15分。在基线期和治疗6个月后采集空腹静脉血样,测定血清促甲状腺激素(TSH)、游离T3(FT3)和游离T4(FT4)浓度。从治疗第一天到治疗期末,HAM-D评分显著降低(P<0.001),12名患者(70.6%)被归类为缓解者。治疗期末FT3浓度显著升高(P=0.015)而FT4浓度降低(P=0.046)。TSH水平未发现显著变化。基线时较高的FT4浓度在基线期和治疗期末均预示着较高的HAM-D评分。此外,治疗期末较高的FT3浓度是较低HAM-D评分的预测指标。米氮平长期治疗可升高FT3水平并降低FT4,可能涉及T4向T3的脱碘过程。